ABB India Dispatches First Locally Made Wind Power Converter From Nelamangala Facility

ABB India has reached a significant manufacturing milestone with the dispatch of its first locally made wind power converter from its Nelamangala facility. This achievement represents a key development in the company's manufacturing capabilities and strategic expansion in the renewable energy sector.

Strategic Manufacturing Development

The dispatch marks ABB India's successful entry into local wind power converter manufacturing, demonstrating the company's commitment to domestic production capabilities. The Nelamangala facility has been equipped to handle the specialized manufacturing requirements for wind power conversion equipment.

Business Acquisition Impact

This manufacturing milestone follows ABB India's acquisition of Gamesa Electric's power electronics business. The acquisition has enabled ABB India to establish local manufacturing capabilities for wind power converters, representing a strategic move to strengthen its position in the renewable energy equipment market.

Development Details:	Information
Product:	Wind Power Converter
Manufacturing Status:	First Local Dispatch
Facility Location:	Nelamangala
Business Context:	Post-Gamesa Electric Acquisition

Manufacturing Significance

The successful dispatch of the first locally manufactured wind power converter demonstrates ABB India's operational readiness and technical capabilities in renewable energy equipment production. This development positions the company to serve the domestic wind energy market with locally produced solutions.

The Nelamangala facility's capability to produce wind power converters represents an important step in ABB India's manufacturing portfolio expansion, particularly in the growing renewable energy sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.11%	-1.32%	-0.29%	-19.12%	+1.56%	+87.98%

Abbott India Limited has received a GST penalty order of ₹2.40 crores from tax authorities, as disclosed in a regulatory filing under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The pharmaceutical company informed the BSE on December 31, 2025, about this development.

Penalty Details and Timeline

The penalty order was issued by the Office of the Principal Commissioner of CGST & Central Excise, Mumbai East. The company received the order on December 30, 2025, covering multiple financial years spanning from 2018-19 to 2023-24.

Parameter	Details
Penalty Amount	₹2,40,46,491
Issuing Authority	Additional Commissioner, GST & Central Excise, Mumbai East
Date of Receipt	December 30, 2025
Financial Years Covered	2018-19, 2019-20, 2021-22 & 2023-24

Nature of Violation

The GST penalty has been levied for the disallowance of Input Tax Credit across the specified financial years. Input Tax Credit allows businesses to reduce their tax liability by claiming credit for taxes paid on inputs used in their business operations.

Company's Response and Impact Assessment

Abbott India has stated that the penalty order will have no material impact on the company's financials, operations, or other business activities. The pharmaceutical major believes that the demand raised by the tax authorities is not maintainable under the applicable regulations.

The company has indicated its intention to challenge the order through the appropriate legal channels. Abbott India is in the process of filing an appeal against the GST penalty order to contest the tax authorities' decision.

Regulatory Compliance

The disclosure was made in compliance with stock exchange regulations, ensuring transparency with shareholders and the investing public. Company Secretary Sangeeta Shetty signed the regulatory intimation, which was filed with the BSE under the company's scrip code 500488.